Literature DB >> 19648688

[Technetium 99Tc methylenediphosphonate inhibits osteoclast formation from PBMCs in patients with rheumatoid arthritis].

Ying Ji1, Xiaocong Huo, Hao Zhang.   

Abstract

OBJECTIVE: To observe the influence of technetium 99Tc methylenediphosphonate (99Tc-MDP) on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) in peripheral blood mononuclear cells in patients with rheumatoid arthritis, and to study the mechanism of 99Tc-MDP in osteoclast differentiation.
METHODS: The monocytes/macrophages were isolated from peripheral blood in patients with rheumatoid arthritis, incubated in RPMI-1640 with receptor activator of NF-kappaB ligand (RANKL, 25 microg/L), macrophage-colony stimulating factor (M-CSF, 25 microg/L) and different concentrations of 99Tc-MDP (5, 10, 20 and 50 mg/L) for 4, 12, and 20 days. Tartrate resistant acid phosphatase staining was used to observe the formation of osteoclasts.
RESULTS: After 12 or 16 days culture of peripheral blood mononuclear cells, plenty of large multinuclear cells could be found on the coverslips. 99Tc-MDP markedly inhibited those changes and the inhibitory effects were increased as the concentration of 99Tc-MDP increased (P<0.05).
CONCLUSION: 99Tc-MDP probably has some protective effect on rheumatoid arthritis by inhibiting osteoclast formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19648688

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  1 in total

1.  99Tc-MDP treatment for the therapy of rheumatoid arthritis, choroidal neovascularisation and Graves' ophthalmopathy.

Authors:  Qian Wu; Yang Ni; Qingrui Yang; Hongsheng Sun
Journal:  Biomed Rep       Date:  2016-02-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.